Ultra-sensitive tumor-informed ctDNA assay predicts survival in advanced melanoma patients treated with ICI treatment

被引：0
|
作者：
Pan, H. [1 ]
Keller, L. [2 ]
Heidrich, I. [3 ]
Kott, J. [3 ]
Abbott, C. W. [1 ]
Boyle, S. [1 ]
Pugh, J. [1 ]
Chen, R. O. [1 ]
Geidel, G. [3 ]
Ronald, S. [3 ]
Schneider, S. [3 ]
Gebhardt, C. [3 ]
Pantel, K. [3 ]
机构：
[1] Personalis Inc, Fremont, CA USA
[2] Canc Univ Inst Toulouse Oncopole, Toulouse, France
[3] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.07.398
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P21-8
引用
收藏
页码：S1373 / S1373
页数：1
相关论文
共 50 条
  • [21] Ultra-sensitive circulating tumor DNA (ctDNA) assay distinguishes partial response (PR) and complete response (CR) with immunotherapy in metastatic renal cell carcinoma (mRCC)
    Chehrazi-Raffle, A.
    Muddasani, R.
    Dizman, N.
    Hsu, J.
    Meza, L.
    Zengin, Z. B.
    Malhotra, J.
    Chawla, N.
    Lyou, Y. M.
    Dorff, T.
    Contente-Cuomo, T.
    Dinwiddie, D.
    McDonald, B.
    Trent, J.
    Murtaza, M.
    Pal, S. K.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1223 - S1223
  • [22] Identification of subjects with locally advanced lung cancer who are likely to respond to standard-of-care chemoradiotherapy by a longitudinal monitoring of circulating tumor DNA (ctDNA) using a comprehensive ultra-sensitive NGS assay
    Vitazka, P.
    Tikoo, N.
    Balasubramanyam, A.
    Xi, L.
    Yaung, S.
    Kwok, E.
    Lovejoy, A.
    Klass, D.
    Heibeck, M.
    Probst, K.
    Rehfeldt, A.
    Meldgaard, E.
    Madsen, A.
    Clement, M.
    Palma, J.
    Sorensen, B.
    Meldgaard, P.
    ANNALS OF ONCOLOGY, 2018, 29 : 491 - 491
  • [23] A six-protein signature predicts response and survival in patients with advanced cutaneous melanoma treated with immunotherapy
    Manda, Srikanth
    Aref, Adel T.
    Sykes, Erin K.
    Williams, Steven G.
    Koh, Jennifer M.
    Humphries, Erin M.
    Bucio-Noble, Daniel
    Lee-Smith, Daniela
    Lucas, Natasha
    Xavier, Dylan
    Menzies, Alexander
    Da Silva, Ines
    Newell, Felicity
    Balleine, Rosemary
    Hains, Peter G.
    Mann, Graham
    Robinson, Phil J.
    Long, Georgina V.
    Wilmott, James
    Zhong, Qing
    Scolyer, Richard A.
    Reddel, Roger R.
    CANCER RESEARCH, 2023, 83 (07)
  • [24] Baseline IPI (immune prognostic index) predicts survival in patients with advanced cervical cancer treated with immune checkpoint inhibitors (ICI)
    Blanc-Durand, F.
    Richardson, M.
    Vuagnat, P.
    Pautier, P.
    Hollebecque, A.
    Varga, A.
    Massard, C.
    Leary, A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [25] Early circulating tumor DNA (ctDNA) changes during treatment with immune checkpoint inhibitors (ICI) as a predictor of clinical outcomes in patients (pts) with advanced stage melanoma/skin cancer.
    Ma, Vincent T.
    Park, Yeonhee
    Patel, Janmesh. D.
    Harris, Madison S.
    Mannino, Matthew C.
    Schehr, Jennifer L.
    Birbrair, Alexander
    Zhao, Shuang
    Lang, Joshua Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : 225 - 225
  • [26] Sensitivity of treatment-free survival (TFS), a novel outcome, to subgroup analyses of patients (pts) with advanced melanoma (MEL) treated with immune checkpoint inhibitors (ICI).
    Mantia, Charlene
    Werner, Lillian
    Rao, Sumati
    Ritchings, Corey
    Tarhini, Ahmad A.
    Atkins, Michael B.
    McDermott, David F.
    Regan, Meredith M.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [27] A tumor and immune related miRNA signature predicts progression-free survival of melanoma patients treated with ipilimumab
    Tarhini, Ahmad
    Vallabhaneni, Priyanka
    Floros, Theofanis
    LaFramboise, William A.
    Benos, Panayiotis V.
    dos Santos, Lucas Santana
    CANCER RESEARCH, 2016, 76
  • [28] BASELINE GLYCOLYTIC TUMOR BURDEN PREDICTS RESPONSE AND SURVIVAL IN NSCLC AND MELANOMA PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS
    Silva, Saulo
    Wanderley, Carlos Wagner
    Marin, Jose Flavio
    De Macedo, Mariana
    Nascimento, Ellen
    Antonacio, Fernanda
    Cunha, Fernando
    de Castro, Gilberto
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A62 - A63
  • [29] Tumor-informed circulating tumor DNA (TI-ctDNA) based molecular residual disease (MRD) detection and relapse risk for patients with stage II-IV melanoma in surgical remission: A single center experience
    Rhea, Logan
    Daniels, Megan
    Sabo, Roy
    Poklepovic, Andrew Stewart
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [30] Circulating tumor-derived DNA (ctDNA) clearance in patients with locally advanced rectal cancer treated with multimodal treatment
    Gervaso, L.
    Ciardiello, D.
    Ascione, L.
    Boldrini, L.
    Guidi, L.
    Valenza, C.
    Gregato, G.
    Funicelli, L.
    Bottiglieri, L.
    De Roberto, G.
    Petz, W.
    Borin, S.
    Romario, U. Fumagalli
    Gerardi, M.
    Bertolini, F.
    Curigliano, G.
    Fazio, N.
    Zampino, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S48 - S48
12345